var pubsImg = new Image();
pubsImg.src = '/gx/eng/about/ind/pharma/pharma2020_chal-a.jpg';
var pubmImg = new Image();
pubmImg.src = '/gx/eng/about/ind/pharma/invest-china-a.gif';
var pubbImg = new Image();
pubbImg.src = '/gx/eng/about/ind/pharma/ph2020-sm-a.jpg';



function makeSpotlight(t,c,l,f,i){
	this.title = t;
	this.copy = c;
	this.link = l;
	this.follow = f;
	this.img = i;
	this.write = writeSpotlight;
}

function writeSpotlight(){
	var str = '';
	str += '<a href="' + this.link + '">';
	str += '<img align="left" hspace="10" border="0" src="' + this.img.src + '"' + 'alt="' + this.title + '"></a>';
	str += '<b>' + this.title + '</b>' + '&nbsp;' + '<br><br>'
	str += this.copy + '&nbsp;';
    str += 'See&nbsp;' + '<a href="' + this.link + '">' + this.follow + '</a>' + '.';
	return str;
}

var newsArray = new Array();
newsArray[0] = new makeSpotlight("<span class=strongtext><font size=3 point-size=12><b>New release</b></font></span><p></p>Pharma 2020: Challenging business models","This paper suggests that alternative business models with varying degrees of collaboration will emerge to provide a basis for the industry to operate more effectively as times change. It also evaluates the advantages and disadvantages of each alternative, their strengths and weaknesses and lists some key questions to make the transition to a new business successful.",'/extweb/industry.nsf/docid/89150A737EFCF98B802575A50032D4A8',"more", pubsImg).write();//Pharma 2020: Challenging business models

newsArray[1] = new makeSpotlight("Investing in China's Pharmaceutical Industry - 2nd Edition ","This paper is the second edition of a paper published by PricewaterhouseCoopers looking into the current pharmaceutical market conditions in China.",'/extweb/industry.nsf/docid/EEF90CB5C1DFC3E28025758C0039EA1B',"more", pubmImg).write();//Investing in China's Pharmaceutical Industry

newsArray[2] = new makeSpotlight("Pharma 2020: Marketing the future - Which path will you take?","This paper discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills.  Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.",'/Extweb/pwcpublications.nsf/docid/B1221EC9D057309F852575610076732C',"more", pubbImg).write();//Pharma 2020: Marketing the future



var nIndex = 0;
var timerID = null;
function rotateSpotlight(){
	var len = newsArray.length;
	if(nIndex >= len)
		nIndex = 0;
	document.getElementById('spotlight').innerHTML = newsArray[nIndex];
	nIndex++;
	timerID = setTimeout('rotateSpotlight()',6500);
}
function pauseSpotlight() {
	if (timerID != null) {
		clearTimeout(timerID);
		timerID = null;
	}
}

function playSpotlight() {
	if (timerID == null) {
		timerID = setTimeout('rotateSpotlight()',650);
	}
}